Jazz Pharmaceuticals plc announced that eight abstracts, including four late-breaking presentations, will be featured at the upcoming American Epilepsy Society $(AES)$ 2025 Annual Meeting, scheduled for December 5-9, 2025, in Atlanta, Georgia. The presentations will focus on new data and real-world evidence related to Epidiolex® (cannabidiol) for treatment-resistant epilepsies. Notably, interim results from the EpiCom trial, which evaluated behavioral outcomes in patients with tuberous sclerosis complex, suggest improvements in non-seizure outcomes. Additional real-world studies using data from the U.S. Optum® Market Clarity Database indicate that Epidiolex initiation in cannabidiol-naïve patients with Dravet Syndrome, Lennox-Gastaut Syndrome, or tuberous sclerosis complex is associated with reduced polypharmacy and healthcare resource utilization at 12 months, with further reductions observed among early-line initiators. All results are scheduled to be presented at the AES 2025 Annual Meeting.